non-small cell lung cancer |
12 |
cancer |
11 |
chemoradiotherapy |
11 |
nasopharyngeal carcinoma |
10 |
neoadjuvant therapy |
10 |
plasma ebv dna |
10 |
quality of life |
10 |
targeted therapy |
10 |
recursive partitioning analysis |
9 |
stage classification |
9 |
survival prediction |
9 |
treatment |
9 |
chinese |
8 |
intensity-modulated radiation therapy |
8 |
non-metastatic |
8 |
oesophageal cancer |
8 |
oesophageal squamous cell carcinoma |
8 |
oesophagectomy |
8 |
prognostic factors |
8 |
radiotherapy |
8 |
-depression |
7 |
breast cancer |
7 |
cancer survivors |
7 |
cancer-related distress |
7 |
distress |
7 |
health-related quality of life |
7 |
illness perception |
7 |
insomnia |
7 |
long-term cancer survivors |
7 |
occupation |
7 |
return to work |
7 |
sleep disturbance |
7 |
sleep quality |
7 |
sleep trajectory |
7 |
thyroid cancer |
7 |
work productivity |
7 |
androgen receptor |
6 |
bq323636.1 |
6 |
chemotherapy |
6 |
concurrent chemoradiotherapy |
6 |
follow up |
6 |
health care |
6 |
immunotherapy |
6 |
local clinical remission |
6 |
metastatic |
6 |
positron emission tomography |
6 |
post-treatment plasma ebv dna |
6 |
prognostic factor |
6 |
survivorship |
6 |
tamoxifen resistance |
6 |
5-fluorouracil |
5 |
aetiology |
5 |
assessment |
5 |
canagliflozin |
5 |
capecitabine |
5 |
cetuximab |
5 |
covid-19 |
5 |
dapagliflozin |
5 |
drug repurposing |
5 |
eq-5d-5 l |
5 |
esophageal cancer |
5 |
gastric cancer |
5 |
her2+ breast cancer |
5 |
her2-targeted therapy |
5 |
medical sciences |
5 |
metastatic brain tumours |
5 |
metastatic colorectal cancer |
5 |
metronomic |
5 |
oral cyclophosphamide |
5 |
palliative |
5 |
psychometric properties |
5 |
radiation therapy |
5 |
radiology and nuclear medicine |
5 |
recurrent |
5 |
reliability |
5 |
responsiveness |
5 |
sodium-glucose co-transporter 2 inhibitor |
5 |
surgery |
5 |
systemic treatment |
5 |
thypro-39 |
5 |
tyrosine kinase inhibitor |
5 |
validity |
5 |
acceptance |
4 |
antithyroid drugs |
4 |
anxiety |
4 |
cisplatin |
4 |
cognitive frailty |
4 |
cognitive function |
4 |
esophageal squamous cell carcinoma |
4 |
esophagectomy |
4 |
frailty |
4 |
graves’ disease |
4 |
hypothyroidism |
4 |
immune checkpoint inhibitor |
4 |
immune checkpoint inhibitors |
4 |
immune-related endocrine dysfunction |
4 |
malignancy |
4 |
neoplasm metastasis |
4 |
older cancer survivors |
4 |
population based cohort |
4 |
prediction |
4 |
radioactive iodine |
4 |
s-1 (combination) |
4 |
squamous cell carcinoma |
4 |
stomach neoplasms |
4 |
target therapy |
4 |
thyroidectomy |
4 |
toxicities |
4 |
vaccination |
4 |
anastrozole |
3 |
ar antagonist |
3 |
aromatase inhibitor resistance |
3 |
brachytherapy |
3 |
cct241533 |
3 |
cervical esophageal cancer |
3 |
chk2 |
3 |
chk2 inhibitor |
3 |
communication |
3 |
cxcr1 |
3 |
direct medical costs |
3 |
dna damage |
3 |
dysphagia |
3 |
intensity modulated radiotherapy |
3 |
interleukin-8 |
3 |
laryngeal preservation |
3 |
novel target |
3 |
oestrogen receptor |
3 |
palliative care |
3 |
srpk1 |
3 |
srsf5 |
3 |
terminal care |
3 |
tma |
3 |
type 2 diabetes mellitus |
3 |
68ga |
2 |
adjuvant radiotherapy |
2 |
advanced gastric adenocarcinoma |
2 |
airway obstruction |
2 |
carcinoma, adenoid cystic |
2 |
case conference |
2 |
colorectal cancer |
2 |
conformal radiotherapy |
2 |
dota |
2 |
geriatrics |
2 |
gpt-4 |
2 |
immune checkpoint inhibition (ici) |
2 |
intensity-modulated radiotherapy |
2 |
maintenance |
2 |
management |
2 |
metastasis |
2 |
microsatellite instability (msi) |
2 |
neuroendocrine tumors |
2 |
older adults |
2 |
oncology |
2 |
pd-l1 |
2 |
peptide receptor radionuclide therapy |
2 |
pet/ct |
2 |
trachea |
2 |
tumor mutational burden (tmb) |
2 |
volumetric modulated arc therapy |
2 |
anesthesiology |
1 |
anthracycline |
1 |
breast cancer specific survival |
1 |
breathlessness |
1 |
capecitabinecy |
1 |
cardiopulmonary resuscitation |
1 |
clinical trials |
1 |
clophosphamide |
1 |
computer-assisted |
1 |
delivery of healthcare |
1 |
do not resuscitate |
1 |
docetaxel |
1 |
dyspnea |
1 |
end of life care |
1 |
ethics |
1 |
geriatric assessment |
1 |
geriatric oncology |
1 |
global health |
1 |
imaging |
1 |
multidisciplinary |
1 |
older patients |
1 |
overall survival |
1 |
palliative medicine |
1 |
pandemics |
1 |
pathology |
1 |
pertuzumab |
1 |
radiation dosage |
1 |
radiotherapy planning |
1 |
scientific conference |
1 |
three-dimensional |
1 |
triple negative breast cancer |
1 |
uterine cervical neoplasms |
1 |